Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Disaggregation of Revenue (Details)

v3.20.1
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Disaggregation of Revenue [Line Items]    
Total revenues $ 14,670 $ 15,583
Americas [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 5,225 2,838
EMEA [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 5,971 7,726
APAC [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 3,474 5,019
Product Sales [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 5,100 7,988
Research and Development Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 9,570 7,595
Performance Enzymes [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 10,874 10,087
Performance Enzymes [Member] | Americas [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 2,999 2,838
Performance Enzymes [Member] | EMEA [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 4,401 2,230
Performance Enzymes [Member] | APAC [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 3,474 5,019
Performance Enzymes [Member] | Product Sales [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 5,100 7,988
Performance Enzymes [Member] | Research and Development Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 5,774 2,099
Novel Biotherapeutics [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 3,796 5,496
Novel Biotherapeutics [Member] | Americas [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 2,226  
Novel Biotherapeutics [Member] | EMEA [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 1,570 5,496
Novel Biotherapeutics [Member] | Research and Development Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues $ 3,796 $ 5,496